“…The clonality of EBV-associated B-cell lymphoproliferative disease may have implications for diagnosis, prognosis, and therapy [Chadburn et al, 1997]. Tumor clonality is typically assessed by one of two methods: either analysis of the genomic structure of the cellular immunoglobulin gene (JH rearrangement assay) or analysis of the structure of the EBV genome terminal repeat region (EBV termini assay) [Brown et al, 1986[Brown et al, , 1988Raab-Traub and Flynn, 1986;Cleary et al, 1988]. A review of the published literature suggests that the results of the JH rearrangement assay and the EBV termini assay are often concordant for the same tumor specimen [Brown et al, 1988;Cleary et al, 1988;Locker and Nalesnik, 1989;Patton et al, 1990;McGrath et al, 1991;Neri et al, 1991;Gulley et al, 1992;Cen et al, 1993;Craig et al, 1993;Delecluse et al, 1993;Shibata et al, 1993;Knowles et al, 1995;Mandell et al, 1999;Ohshima et al, 1999], but numerous examples of discordant results have been noted [Locker and Nalesnik, 1989;Patton et al, 1990;McGrath et al, 1991;Cen et al, 1993;Delecluse et al, 1993;Knowles et al, 1995;Ohshima et al, 1999;Sadahira et al, 2001;Nador et al, 2003].…”